WTW: Employer GLP-1 Weight-Loss Coverage Falls to 53% from 57%, First Drop in 3 Years

4.2 · 4d ago · US · FINANCE

The Facts

  • A WTW annual health benefits survey fielded over the summer found 53% of employers with more than 100 employees cover GLP-1s for weight loss, down from 57% in 2025, the first decline in three years. CNBC only
  • 16% of employers in the WTW survey said they cover GLP-1s now but are considering removing them, up from 9% last year. CNBC only
  • A Marsh survey of over 1,800 US employers projects health insurance cost per employee will rise 8.2% on average in 2027, the largest increase since 2003, with GLP-1 use accounting for one percentage point of the growth. CNBC only
  • Covering GLP-1s for weight loss typically costs employers in the mid-$500s to mid-$600s per user per month. CNBC only
  • 8% of employers in the WTW survey direct workers to buy GLP-1s through direct-to-consumer channels such as NovoCare or LillyDirect, and 28% are planning or considering it. CNBC only
Dive deeper · 5 more factsShow less
  • Gallagher's Seth Friedman estimated 20% to 30% of the firm's clients have dropped coverage for 2027 and are sending employees to direct-purchase options. CNBC only
  • Gallup reports 11% of US adults took GLP-1 medications for weight loss in 2026, up from 3% in 2024; 15% report having used them at some point. CNBC only
  • Self-pay starting prices for the lowest dose of Wegovy are $149 a month for the pill and $199 a month for the shot; Novo Nordisk says promotional pricing may be modified or canceled in 2027. Zepbound starts at $299 a month. CNBC only
  • Bank of America CEO Brian Moynihan said in August the bank spends about $250 million or more on GLP-1s, up from zero four or five years ago, and called it a good investment. CNBC only
  • Some employers are moving to direct-to-employer models that reimburse part of workers' out-of-pocket costs, or contracting third-party weight-management programs such as CVS Weight Management, Noom, Omada Health, UnitedHealthcare, Vida and Virta. CNBC only

Context

Rising healthcare costs are leading more US employers to drop or scale back coverage of GLP-1 drugs for weight loss ahead of 2027, according to WTW and Marsh surveys cited by CNBC.

Some employers are redirecting workers to manufacturers' direct-to-consumer programs, reimbursing part of out-of-pocket costs, or offering third-party weight-management programs instead. Some large employers, such as Bank of America, continue to cover the drugs.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 2.

5 Informed Citizen A survey-reported 4-point drop in employer GLP-1 weight-loss coverage, with some employers shifting costs to workers, is newsworthy and affects many employees, but it is survey data rather than a concrete policy change with immediate broad impact.
5 Critical Reader A measurable decline in employer GLP-1 weight-loss coverage (57% to 53%, first drop in three years) plus projected 2027 cost increases affects many workers and employers, though it is survey-based and from a single source, so moderate importance.
4 News Editor This is a survey-based trend story about employer benefit decisions affecting workers' drug coverage, a concrete but niche business and health-benefits development with limited immediate impact compared with broader news.
4 Science & Tech Analyst This is a survey-based report of a modest 4-point decline in employer GLP-1 coverage, a trend affecting employees' benefits but with limited immediate, concrete impact beyond a niche corporate benefits audience.
4 Policy Expert The story reports survey findings and employer coverage trends, which are notable for benefits markets but not enacted laws, rulings, or government actions, so its impact is limited to a moderate, niche audience.
4 Business Analyst This is a survey-based trend story about a moderate decline in employer GLP-1 coverage with real cost implications, but it reports no discrete market-moving action or regulatory change, so it sits in the minor-to-moderate range.
3 Global Affairs Analyst This survey-based report describes a modest 4-point decline in employer GLP-1 coverage and shifting benefit designs, which is a notable trend for workers and insurers but not a major breaking event with widespread immediate impact.

Source

← All stories